Is NNBXF or DIVO a better dividend investment in 2026?

NNBXF currently yields 21.98% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: NNBXF offers higher current income.

What is the dividend yield difference between NNBXF and DIVO?

NNBXF has a forward dividend yield of 21.98% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 15.49 percentage points.

Home › Compare › NNBXF vs DIVO

NNBXF vs DIVO: Dividend Comparison 2026

NNBXF yields 21.98% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NNBXF wins by $51.7K in total portfolio value

INVESTMENT

TIME HORIZON10 years

NNBXF

● Live price

21.98%

Share price

$9.10

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$82.4K

Annual income

$8,278.86

Full NNBXF calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — NNBXF vs DIVO

📍 NNBXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NNBXF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NNBXF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NNBXF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NNBXF

Annual income on $10K today (after 15% tax)

$1,868.13/yr

After 10yr DRIP, annual income (after tax)

$7,037.03/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, NNBXF beats the other by $6,202.60/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NNBXF + DIVO for your $10,000?

NNBXF: 50%DIVO: 50%

100% DIVO50/50100% NNBXF

Portfolio after 10yr

$56.5K

Annual income

$4,630.27/yr

Blended yield

8.19%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NNBXF buys

DIVO buys

No recent congressional trades found for NNBXF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNNBXFDIVO

Forward yield	21.98% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$82.4K ✓	$30.7K
Annual income after 10y	$8,278.86 ✓	$981.68
Total dividends collected	$49.1K ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: NNBXF vs DIVO ($10,000, DRIP)

Year	NNBXF Portfolio	NNBXF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$12,898	$2,197.80	$11,349	$649.42	+$1.5K → NNBXF
2	$16,450	$2,649.24	$12,833	$688.83	+$3.6K → NNBXF
3	$20,759	$3,157.79	$14,459	$727.90	+$6.3K → NNBXF
4	$25,937	$3,724.32	$16,238	$766.49	+$9.7K → NNBXF
5	$32,101	$4,348.78	$18,179	$804.47	+$13.9K → NNBXF
6	$39,378	$5,030.23	$20,293	$841.71	+$19.1K → NNBXF
7	$47,902	$5,766.90	$22,591	$878.14	+$25.3K → NNBXF
8	$57,811	$6,556.21	$25,087	$913.65	+$32.7K → NNBXF
9	$69,253	$7,394.84	$27,791	$948.18	+$41.5K → NNBXF
10	$82,379	$8,278.86	$30,718	$981.68	+$51.7K → NNBXF

NNBXF vs DIVO: Complete Analysis 2026

NNBXF — Stock

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Full NNBXF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this NNBXF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NNBXF vs SCHD NNBXF vs JEPI NNBXF vs O NNBXF vs KO NNBXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.